Filing Flows › Comparisons › STOK vs CAPR
Stoke Therapeutics vs Capricor Therapeutics: STOK and CAPR compared
Stoke Therapeutics is the larger company: $11.3M of revenue in its latest quarter (Q3 2026) against $11.1M for Capricor Therapeutics (Q4 2024). Stoke Therapeutics is growing faster (+6% against -8% a year earlier). Capricor Therapeutics is more profitable, with an operating margin of -69.1% against -686.9%.
Where the money goes: STOK and CAPR
Stoke Therapeutics (STOK) · Q3 2026
Stoke Therapeutics, Q3 2026: revenue $11.3M (+6% year over year), operating margin -686.9%, net loss $73.6M, operating cash flow −$62.7M. The chart follows the revenue to costs, profit and cash.
Capricor Therapeutics (CAPR) · Q4 2024
Capricor Therapeutics, Q4 2024: revenue $11.1M (-8% year over year), operating margin -69.1%, net loss $7.1M, operating cash flow −$14.8M. The chart follows the revenue to costs, profit and cash.
| Stoke Therapeutics (STOK) | Capricor Therapeutics (CAPR) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q4 2024 |
| Revenue | $11.3M | $11.1M |
| Revenue growth, Y/Y | +6% | -8% |
| Operating margin | -686.9% | -69.1% |
| Net earnings | −$73.6M | −$7.1M |
| Net margin | -654.3% | -63.9% |
| Operating cash flow | −$62.7M | −$14.8M |
Questions
Which is bigger, Stoke Therapeutics or Capricor Therapeutics?
Stoke Therapeutics is the larger company: $11.3M of revenue in its latest quarter (Q3 2026) against $11.1M for Capricor Therapeutics (Q4 2024).
Is Stoke Therapeutics or Capricor Therapeutics growing faster?
Stoke Therapeutics is growing faster (+6% against -8% a year earlier).
Which is more profitable, Stoke Therapeutics or Capricor Therapeutics?
Capricor Therapeutics is more profitable, with an operating margin of -69.1% against -686.9%.
More: Stoke Therapeutics earnings · how Stoke Therapeutics makes money · Capricor Therapeutics earnings · how Capricor Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-K filed Mar 26, 2025). Fiscal quarters can end on different dates. Not investment advice.